Sartorius AG's Q3 2024 Results Show Stability Amid Market Fluctuations

Sartorius AG reported its nine-month results with sales revenue nearing prior-year levels and a rise in orders. Despite a slight 2.0% decrease in group sales revenue, order intake showed a notable 6.6% increase. The underlying EBITDA margin was robust at 27.7%, benefiting from an efficiency program.

The Bioprocess Solutions Division saw steady sales thanks to a recovering consumables market. However, the Lab Products & Services Division faced challenges due to weak end markets, especially in China. Regionally, EMEA showed growth, while the Americas and Asia/Pacific regions saw declines.

The company's financial health remains strong, with a rise in net operating cash flow and a reduced net debt ratio. Investment in global infrastructure supports Sartorius’ growth ambitions, as it remains confident in fulfilling its full-year 2024 guidance.